KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBIT (2016 - 2025)

Arbutus Biopharma's EBIT history spans 13 years, with the latest figure at -$8.7 million for Q3 2025.

  • For Q3 2025, EBIT rose 59.61% year-over-year to -$8.7 million; the TTM value through Sep 2025 reached -$46.8 million, up 43.7%, while the annual FY2024 figure was -$76.3 million, 2.28% up from the prior year.
  • EBIT for Q3 2025 was -$8.7 million at Arbutus Biopharma, down from $1.5 million in the prior quarter.
  • Across five years, EBIT topped out at $1.5 million in Q2 2025 and bottomed at -$25.7 million in Q1 2025.
  • The 5-year median for EBIT is -$18.4 million (2021), against an average of -$17.2 million.
  • The largest annual shift saw EBIT tumbled 58.68% in 2023 before it soared 106.89% in 2025.
  • A 5-year view of EBIT shows it stood at -$20.8 million in 2021, then fell by 8.49% to -$22.6 million in 2022, then grew by 8.04% to -$20.7 million in 2023, then soared by 32.84% to -$13.9 million in 2024, then skyrocketed by 37.85% to -$8.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's EBIT are -$8.7 million (Q3 2025), $1.5 million (Q2 2025), and -$25.7 million (Q1 2025).